Natco Pharma Limited has informed the Exchange regarding a press release dated September 18, 2025, titled "NATCO's Pharma division located in Kothur, Hyderabad, India has now received Establishment Inspection Report (EIR) classifying the facility as "Voluntary Action Indicated (VAI)" from the U.S. Food and Drug Administration (FDA)
NATCOPHARM · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Awaiting price reaction for this filing.
Natco Pharma's pharmaceutical manufacturing facility at Kothur, Hyderabad has received a favorable outcome from the U.S. FDA. The FDA issued an Establishment Inspection Report (EIR) classifying the plant as "Voluntary Action Indicated (VAI)", which is the most positive inspection outcome - meaning no objectionable conditions were found that require regulatory action. The facility can continue operating and supplying to the U.S. market without restrictions. This clears any prior uncertainty about the plant's compliance status and supports uninterrupted exports to the U.S., which is a key regulated market for Natco's generic pharmaceutical business.
Positive for shareholders. The VAI classification removes regulatory overhang and allows the Kothur plant to keep serving the U.S. market without disruption, supporting exports and revenue from regulated markets. No compliance remediation costs or supply interruptions are expected from this facility.